Company reports $0.32M quarterly revenue, exceeding expectations as GAAP EPS matches forecasts at -$0.02.
IGC Pharma posted Q1 revenue of $0.32M, beating estimates by $0.09M despite a 3% year-over-year decline. GAAP earnings per share came in at -$0.02, aligning with projections.
The company’s total outstanding debt stood at $917 thousand as of March 31, 2026. Following the quarter, IGC Pharma secured additional debt of approximately $585 thousand.
No immediate market reaction was disclosed in the release.